September 4
IN THIS ISSUE / September 4, 2019
- New Drug Application submitted for rosacea topical treatment
- DW Insights and Inquiries: Parabens — A common allergen with lots of hype and no real harm
- Feedback requested: AAD/NPF draft guidelines for the management of psoriasis with non-biologics
- AAD media coverage on sun protection earns one billion media impressions
- Nominations sought for 2020 Academy election
New Drug Application submitted for rosacea topical treatment
A New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for FMX103, an investigational treatment for moderate-to-severe papulopustular rosacea in patients 18 years of age and older. The drug is a topical foam formulation of minocycline (1.5%). Results from two phase 3 trials showed that at the end of 12 weeks, there was statistically significant improvement with FMX103 compared with vehicle foam, and the treatment was generally well tolerated.
Read about the updated rosacea classification system and updates in treatment in Dermatology World.
Related content:
- The many uses of microneedling – Dermatology World (September 2018)
- The rosy reality of coffee – DW Insights and Inquiries (November 2018)
- Unlocking the mysteries of rosacea – Dermatology World (August 2013)
- Academy product: Rosacea pamphlets
DW Insights and Inquiries: Parabens — A common allergen with lots of hype and no real harm
Every year for the past 20 years, the American Contact Dermatitis Society (ACDS) has highlighted an allergen. Most often, the particular allergen is selected because it is new and emerging, such as methylisothiazolinone in 2013. Sometimes, it is because the allergen is well known, but now has new exposure routes. Such was the case with nickel, the allergen of the year for 2008, because of exposure to both biomedical devices and cell phones. Paraphenylenediamine, allergen of the year for 2006, was chosen because of new exposures via temporary tattoos. Occasionally, the ACDS highlights allergens because they are the subject of much discussion but are not believed to be significant — such was the case with thimerosal, the contact allergen of the year in 2002, and now with parabens, the contact allergen of the year for 2019.
Parabens are very common preservatives that have been used in personal care products, food, and pharmaceuticals for decades. Recent data from the ACDS Contact Allergen Management Program (CAMP) revealed that 19% of all products contained parabens. They have little allergenicity, especially when compared to other preservatives. Reactions to parabens are rare. The use of parabens has become commonplace because of their low toxicity, safety profile, and cost. The most commonly used parabens are methylparaben, ethylparaben, propylparaben, and butylparaben. They can be utilized either alone or in combination. Keep reading!
Feedback requested: AAD/NPF draft guidelines for the management of psoriasis with non-biologics
The American Academy of Dermatology is requesting feedback from members about its draft Guidelines of Care for the Management of Psoriasis with Systemic Non-biological Therapies. AAD members are encouraged to provide comments on the draft guidelines before the comment period closes Sept. 12.
Guidelines serve as decision-making and educational aids for clinical practice to support and improve quality dermatologic care, and are used as the framework for quality measurement, reimbursement decisions, advocacy efforts, public messaging, and the identification of research gaps. When finalized, these evidence-based guidelines will be submitted for publication in the Journal of the American Academy of Dermatology and will be considered current for five years from the date of publication.
View the Academy’s current and upcoming clinical guidelines in the AADA Practice Management Center.
Related content:
- Collaboration and diverse expertise strengthen clinical practice guidelines – Dermatology World ( February 2019)
- New urticaria guidelines update antihistamine recommendations – Dermatology World (June 2018)
- Setting the standards – Dermatology World (July 2016)
AAD media coverage on sun protection earns one billion media impressions
Sun protection and skin cancer risk continue to be hot topics in the news. Throughout the year, and especially during the summer months, the Academy helps journalists educate the public about skin cancer prevention and detection using tips from board-certified dermatologists. As of Aug. 15, interviews with dermatologists and/or the Academy’s key messages about the importance of sun protection and skin cancer prevention were included in more than 1,044 local and national news stories, resulting in more than 1.2 billion media impressions and an estimated ad value of more than $3.8 million.
Check out some of the headlines:
The TODAY Show:
Two melanoma survivors share their skin cancer stories, and AAD member Jeanie Downie, MD, helps educate viewers about the importance of early detection and the ABCDEs of melanoma.
Good Morning America:
After a young melanoma survivor shares how early detection helped save her life, AAD member Whitney Bowe, MD, shares how to effectively apply sunscreen and what to look for in a cancerous mole.
USA Today:
AAD President George Hruza, MD, MBA, and AAD members Henry Lim, MD, and David Leffell, MD, discuss the FDA’s proposed sunscreen rule and remind readers that sunscreen remains an important way to reduce the risk of skin cancer.
The Oprah Magazine:
AAD member Adam Friedman, MD, shares the ABCDEs of melanoma and encourages readers to see a board-certified dermatologist if they see anything new or suspicious on their skin.
Related content:
- What is the USPSTF and what do its skin cancer counseling recommendations mean for the specialty and patients? – Dermatology World (April 2019)
- Why see a board-certified dermatologist?
Nominations sought for 2020 Academy election
Nominations for Officers, Directors, and Nominating Committee Member Representatives (West Region) are now being accepted through Oct. 1. To view reference materials, or submit a nomination and letter of support, visit staging.aad.org/aadnominations or email callfornominations@aad.org.
